Literature DB >> 27885165

Neoadjuvant chemotherapy in breast cancers.

Shahla Masood1,2.   

Abstract

With advances in science and technology, there are more innovations in the approach to management of patients with breast cancer. Neoadjuvant chemotherapy that is designed to be used prior to surgical removal of a tumor has received significant attention. Currently, neoadjuvant chemotherapy is offered to patients with locally advanced breast cancer and also those breast cancer patients who may benefit from size reduction before conservation therapy. There is now sufficient evidence that if neoadjuvant chemotherapy leads to complete pathologic response, the patient will enjoy a better outcome. Therefore, assessment of the degree of response to neoadjuvant chemotherapy has a major impact on patient selection and the follow-up management of each patient and defines patient outcome.
© The Author(s) 2016.

Entities:  

Keywords:  breast cancer; breast pathology report; neoadjuvant chemotherapy

Mesh:

Substances:

Year:  2016        PMID: 27885165      PMCID: PMC5373271          DOI: 10.1177/1745505716677139

Source DB:  PubMed          Journal:  Womens Health (Lond)        ISSN: 1745-5057


  60 in total

1.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

2.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Authors:  Savannah C Partridge; Jessica E Gibbs; Ying Lu; Laura J Esserman; Debasish Tripathy; Dulcy S Wolverton; Hope S Rugo; E Shelley Hwang; Cheryl A Ewing; Nola M Hylton
Journal:  AJR Am J Roentgenol       Date:  2005-06       Impact factor: 3.959

3.  The Perfect Pathology Report After Neoadjuvant Therapy.

Authors:  Caterina Marchiò; Francesca Maletta; Laura Annaratone; Anna Sapino
Journal:  J Natl Cancer Inst Monogr       Date:  2015-05

4.  Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis.

Authors:  Robert T Pu; Anne F Schott; David E Sturtz; Kent A Griffith; Celina G Kleer
Journal:  Am J Surg Pathol       Date:  2005-03       Impact factor: 6.394

5.  Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.

Authors:  A Romero; A Prat; J A García-Sáenz; N Del Prado; A Pelayo; V Furió; J M Román; M de la Hoya; E Díaz-Rubio; C M Perou; T Cladés; M Martín
Journal:  Clin Transl Oncol       Date:  2013-08-02       Impact factor: 3.405

6.  American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.

Authors:  Lisa A Carey; Richard Metzger; E Claire Dees; Frances Collichio; Carolyn I Sartor; David W Ollila; Nancy Klauber-DeMore; Jan Halle; Lynda Sawyer; Dominic T Moore; Mark L Graham
Journal:  J Natl Cancer Inst       Date:  2005-08-03       Impact factor: 13.506

7.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

8.  Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.

Authors:  Stefan Glück; Femke de Snoo; Justine Peeters; Lisette Stork-Sloots; George Somlo
Journal:  Breast Cancer Res Treat       Date:  2013-06-12       Impact factor: 4.872

9.  Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.

Authors:  J Lee; Y H Im; S H Lee; E Y Cho; Y L Choi; Y H Ko; J H Kim; S J Nam; H J Kim; J S Ahn; Y S Park; H Y Lim; B K Han; J H Yang
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-17       Impact factor: 3.333

10.  A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.

Authors:  E Provenzano; A-L Vallier; R Champ; K Walland; S Bowden; A Grier; N Fenwick; J Abraham; M Iddawela; C Caldas; L Hiller; J Dunn; H M Earl
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

View more
  15 in total

1.  MicroRNA-130a reduces drug resistance in breast cancer.

Authors:  Jin Huang; Min Zhao; Hongguang Hu; Jin Wang; Lin Ang; Li Zheng
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

2.  Impact of modern personalized treatment of breast cancer on surgical attitude and outcomes.

Authors:  Ciprian Tănăsescu; Dragos Serban; Andrei Moisin; Carmen Popa; Ramona Coca; George Iancu; Mihail Silviu Tudosie; Daniel Ovidiu Costea; Bogdan Socea; Corneliu Tudor; Gabriel Andrei Gangura; Laura Carina Tribus; Gabriel Catalin Smarandache
Journal:  Exp Ther Med       Date:  2021-11-17       Impact factor: 2.447

Review 3.  Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).

Authors:  Abeer H Abdelhafez; Benjamin C Musall; Wei T Yang; Gaiane M Rauch; Beatriz E Adrada; KennethR Hess; Jong Bum Son; Ken-Pin Hwang; Rosalind P Candelaria; Lumarie Santiago; Gary J Whitman; Huong T Le-Petross; Tanya W Moseley; Elsa Arribas; Deanna L Lane; Marion E Scoggins; Jessica W T Leung; Hagar S Mahmoud; Jason B White; Elizabeth E Ravenberg; Jennifer K Litton; Vicente Valero; Peng Wei; Alastair M Thompson; Stacy L Moulder; Mark D Pagel; Jingfei Ma
Journal:  Breast Cancer Res Treat       Date:  2020-09-13       Impact factor: 4.872

4.  Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype.

Authors:  Noura Al-Zeheimi; Sirin A Adham
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

5.  Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 & SATB1 in HER-2-Positive breast cancer patients.

Authors:  Zhi Chen; Mei-Xiang Sang; Cui-Zhi Geng; Wei Hao; Hui-Qun Jia
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 1.088

6.  What is known about melatonin, chemotherapy and altered gene expression in breast cancer.

Authors:  Carlos Martínez-Campa; Javier Menéndez-Menéndez; Carolina Alonso-González; Alicia González; Virginia Álvarez-García; Samuel Cos
Journal:  Oncol Lett       Date:  2017-02-10       Impact factor: 2.967

7.  Treatment of Saos-2 osteosarcoma cells with diallyl trisulfide is associated with an increase in calreticulin expression.

Authors:  Wen-Peng Xie; Yue Zhang; Yong-Kui Zhang; Gang Li; Jian Xin; Rong-Xiu Bi; Chuan-Jie Li
Journal:  Exp Ther Med       Date:  2018-04-05       Impact factor: 2.447

8.  Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10-year (2006-2015) retrospective hospitalization summary report-based study.

Authors:  Xiaoyuan Bao; Kexin Sun; Xin Tian; Qiongzhou Yin; Meng Jin; Na Yu; Hanfang Jiang; Jun Zhang; Yonghua Hu
Journal:  Thorac Cancer       Date:  2018-04-06       Impact factor: 3.500

Review 9.  Awareness and current knowledge of breast cancer.

Authors:  Muhammad Akram; Mehwish Iqbal; Muhammad Daniyal; Asmat Ullah Khan
Journal:  Biol Res       Date:  2017-10-02       Impact factor: 5.612

10.  Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment.

Authors:  Mariel Garcia-Chagollan; Irma Edith Carranza-Torres; Pilar Carranza-Rosales; Nancy Elena Guzmán-Delgado; Humberto Ramírez-Montoya; María Guadalupe Martínez-Silva; Ignacio Mariscal-Ramirez; Carlos Alfredo Barrón-Gallardo; Ana Laura Pereira-Suárez; Adriana Aguilar-Lemarroy; Luis Felipe Jave-Suárez
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.